Open AccessChildhood pemphigus vulgaris successfully treated with rituximab
Author(s) -
Amrinder J. Kanwar,
Gitesh U Sawatkar,
Keshavamurthy Vinay,
Takashi Hashimoto
Publication year - 2012
Publication title -
indian journal of dermatology, venereology, and leprology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.514
H-Index - 45
eISSN - 0973-3922
pISSN - 0378-6323
DOI - 10.4103/0378-6323.100587
Subject(s) - rituximab , pemphigus vulgaris , pemphigus , medicine , dexamethasone , dermatology , refractory (planetary science) , immunology , lymphoma , physics , astrobiology
Pemphigus is a potentially fatal autoimmune epidermal bullous disorder. Rituximab is a novel therapy for the treatment of refractory pemphigus. However, there is limited clinical data on safety and efficacy of rituximab in pediatric age group. Herein, we report an 11-year-old boy of childhood pemphigus vulgaris who failed to respond to dexamethasone pulse therapy and was subsequently treated with rituximab and achieved complete remission.